Symbols / CDTX
CDTX Chart
About
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.96B |
| Enterprise Value | 6.54B | Income | -184.80M | Sales | — |
| Book/sh | 14.40 | Cash/sh | 13.36 | Dividend Yield | — |
| Payout | 0.00% | Employees | 38 | IPO | Apr 15, 2015 |
| P/E | — | Forward P/E | -30.70 | PEG | — |
| P/S | inf | P/B | 15.37 | P/C | — |
| EV/EBITDA | -40.95 | EV/Sales | — | Quick Ratio | 4.40 |
| Current Ratio | 4.62 | Debt/Eq | 0.47 | LT Debt/Eq | — |
| EPS (ttm) | -11.20 | EPS next Y | -7.21 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -29.35% |
| ROE | -68.70% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 31.45M |
| Shs Float | 23.11M | Short Float | 6.43% | Short Ratio | 1.34 |
| Short Interest | — | 52W High | 221.42 | 52W Low | 15.22 |
| Beta | 1.53 | Avg Volume | 1.43M | Volume | 2.69M |
| Target Price | $221.50 | Recom | Hold | Prev Close | $221.38 |
| Price | $221.38 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$221.50
Mean price target
2. Current target
$221.38
Latest analyst target
3. DCF / Fair value
$-18.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$221.38
Low
$221.50
High
$221.50
Mean
$221.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-18 | down | Guggenheim | Buy → Neutral | — |
| 2025-11-14 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-11-14 | down | Needham | Buy → Hold | — |
| 2025-11-07 | main | RBC Capital | Outperform → Outperform | $145 |
| 2025-11-07 | main | Needham | Buy → Buy | $135 |
| 2025-10-21 | reit | HC Wainwright & Co. | Buy → Buy | $150 |
| 2025-10-16 | init | Morgan Stanley | — → Overweight | $190 |
| 2025-10-10 | init | JP Morgan | — → Overweight | $200 |
| 2025-10-09 | main | WBB Securities | Strong Buy → Strong Buy | $199 |
| 2025-10-09 | main | HC Wainwright & Co. | Buy → Buy | $150 |
| 2025-10-03 | main | JMP Securities | Market Outperform → Market Outperform | $173 |
| 2025-09-26 | main | HC Wainwright & Co. | Buy → Buy | $110 |
| 2025-09-25 | main | Guggenheim | Buy → Buy | $167 |
| 2025-09-24 | main | Needham | Buy → Buy | $100 |
| 2025-09-24 | reit | WBB Securities | Strong Buy → Strong Buy | $123 |
| 2025-09-22 | main | WBB Securities | Strong Buy → Strong Buy | $123 |
| 2025-08-08 | main | JMP Securities | Market Outperform → Market Outperform | $66 |
| 2025-08-08 | main | Needham | Buy → Buy | $74 |
| 2025-08-08 | main | HC Wainwright & Co. | Buy → Buy | $74 |
| 2025-06-30 | main | JMP Securities | Market Outperform → Market Outperform | $59 |
- Cidara Therapeutics, Inc. (CDTX) Stock Report: Navigating a Biotech Trail with a Market Cap of $6.96 Billion - DirectorsTalk Interviews hu, 19 Feb 2026 08
- Fund Update: New $40.8M $CDTX stock position opened by Neuberger Berman Group LLC - Quiver Quantitative Fri, 13 Feb 2026 18
- Published on: 2026-02-25 12:36:01 - baoquankhu1.vn ue, 24 Feb 2026 23
- CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza - Yahoo Finance Fri, 10 Oct 2025 07
- Cidara Therapeutics Stock Doubles On Possible Merck Acquisition Deal for $9.2 Billion - TIKR.com Mon, 17 Nov 2025 08
- CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program - Nasdaq Fri, 26 Sep 2025 07
- Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - Stock Titan Mon, 13 Oct 2025 07
- This Biotech's Stock Price More Than Doubled on Friday. Here's Why. - Investopedia Fri, 14 Nov 2025 08
- Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal - Investor's Business Daily Fri, 14 Nov 2025 08
- Merck to acquire Cidara for $221.50/share in $9.2 billion deal; CDTX soars (MRK:NYSE) - Seeking Alpha Fri, 14 Nov 2025 08
- Stocks making big premarket moves: WBD, CDTX, AVDL and more - CNBC Fri, 14 Nov 2025 08
- Analysts Shift to Hold as Cidara’s (CDTX) Recent Acquisition Deal Caps Upside - Yahoo Finance Sun, 23 Nov 2025 08
- $CDTX stock is up 105% today. Here's what we see in our data. - Quiver Quantitative Fri, 14 Nov 2025 08
- Cidara's Narrow Spread: The Bidding War Is Over (CDTX) - Seeking Alpha Fri, 14 Nov 2025 08
- Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid - Yahoo Finance Sat, 15 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 450 | — | — | Stock Gift at price 0.00 per share. | DAVARPANAH NICOLE NEGAR | Officer | — | 2025-12-29 00:00:00 | D |
| 1 | 51379 | — | — | Stock Gift at price 0.00 per share. | STEIN JEFFREY | Chief Executive Officer | — | 2025-12-22 00:00:00 | D/I |
| 2 | 9959 | 2191747.0 | — | Sale at price 220.08 per share. | WARD SHANE M | Chief Operating Officer | — | 2025-12-10 00:00:00 | D |
| 3 | 9959 | 188761.0 | — | Conversion of Exercise of derivative security at price 16.65 - 20.20 per share. | WARD SHANE M | Chief Operating Officer | — | 2025-12-10 00:00:00 | D |
| 4 | 474 | 29797.0 | — | Sale at price 62.86 per share. | DAVARPANAH NICOLE NEGAR | Officer | — | 2025-09-11 00:00:00 | D |
| 5 | 2272727 | 99999988.0 | — | Purchase at price 44.00 per share. | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-26 00:00:00 | I |
| 6 | 3320 | 73896.0 | — | Purchase at price 21.71 - 23.44 per share. | MINEO CHRYSA | Director | — | 2025-06-03 00:00:00 | D |
| 7 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | DAVARPANAH NICOLE NEGAR | Officer | — | 2025-05-01 00:00:00 | D |
| 8 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | WARD SHANE M | Chief Operating Officer | — | 2025-03-31 00:00:00 | D |
| 9 | 1664 | 36542.0 | — | Sale at price 21.96 per share. | WARD SHANE M | Chief Operating Officer | — | 2025-03-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -175.87M | -26.94M | -33.36M | -42.26M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -170.29M | -25.08M | -33.58M | -42.47M |
| ReconciledDepreciation | 233.00K | 118.00K | 143.00K | -1.23M |
| ReconciledCostOfRevenue | 1.52M | 0.00 | ||
| EBITDA | -175.87M | -26.94M | -33.36M | -42.26M |
| EBIT | -176.10M | -27.06M | -33.50M | -42.26M |
| NetInterestIncome | 5.81M | 2.00M | 191.00K | -212.00K |
| InterestIncome | 5.81M | 2.00M | 191.00K | |
| NormalizedIncome | -170.29M | -25.08M | -33.58M | -42.47M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -169.83M | -22.93M | -33.58M | -42.47M |
| TotalExpenses | 177.38M | 50.34M | 97.95M | 91.83M |
| TotalOperatingIncomeAsReported | -176.10M | -27.06M | -33.50M | -42.26M |
| DilutedAverageShares | 6.35M | 4.37M | 3.49M | 2.62M |
| BasicAverageShares | 6.35M | 4.37M | 3.49M | 2.62M |
| DilutedEPS | -26.75 | -5.25 | -8.60 | -16.20 |
| BasicEPS | -26.75 | -5.25 | -8.60 | -16.20 |
| DilutedNIAvailtoComStockholders | -169.83M | -22.93M | -33.58M | -42.47M |
| NetIncomeCommonStockholders | -169.83M | -22.93M | -33.58M | -42.47M |
| NetIncome | -169.83M | -22.93M | -33.58M | -42.47M |
| NetIncomeIncludingNoncontrollingInterests | -169.83M | -22.93M | -33.58M | -42.47M |
| NetIncomeDiscontinuousOperations | 464.00K | 2.15M | ||
| NetIncomeContinuousOperations | -170.29M | -25.08M | -33.58M | -42.47M |
| TaxProvision | 0.00 | 15.00K | 272.00K | 0.00 |
| PretaxIncome | -170.29M | -25.07M | -33.31M | -42.47M |
| NetNonOperatingInterestIncomeExpense | 5.81M | 2.00M | 191.00K | -212.00K |
| TotalOtherFinanceCost | -191.00K | 212.00K | ||
| InterestIncomeNonOperating | 5.81M | 2.00M | 191.00K | |
| OperatingIncome | -176.10M | -27.06M | -33.50M | -42.26M |
| OperatingExpense | 177.38M | 50.34M | 97.95M | 91.83M |
| ResearchAndDevelopment | 156.76M | 36.76M | 77.41M | 73.09M |
| SellingGeneralAndAdministration | 20.61M | 13.58M | 20.55M | 18.74M |
| GeneralAndAdministrativeExpense | 20.61M | 13.58M | 20.55M | 18.74M |
| OtherGandA | 20.61M | 13.58M | 20.55M | 18.74M |
| GrossProfit | 62.38M | 64.45M | ||
| CostOfRevenue | 1.52M | 0.00 | ||
| TotalRevenue | 1.27M | 23.28M | 64.45M | 49.57M |
| OperatingRevenue | 1.27M | 23.28M | 64.45M | 49.57M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 10.95M | 4.53M | 3.62M | 3.39M |
| ShareIssued | 10.95M | 4.53M | 3.62M | 3.39M |
| TotalDebt | 3.58M | 4.88M | 1.21M | 5.06M |
| TangibleBookValue | 163.31M | -8.21M | -14.44M | 21.57M |
| InvestedCapital | 163.31M | -8.21M | -14.44M | 24.16M |
| WorkingCapital | 161.18M | -6.56M | 3.69M | 37.68M |
| NetTangibleAssets | 163.31M | -8.21M | -14.44M | 21.57M |
| CapitalLeaseObligations | 3.58M | 4.88M | 1.21M | 2.47M |
| CommonStockEquity | 163.31M | -8.21M | -14.44M | 21.57M |
| TotalCapitalization | 163.31M | -8.21M | -14.44M | 21.57M |
| TotalEquityGrossMinorityInterest | 163.31M | -8.21M | -14.44M | 21.57M |
| StockholdersEquity | 163.31M | -8.21M | -14.44M | 21.57M |
| RetainedEarnings | -611.26M | -441.43M | -418.50M | -377.17M |
| AdditionalPaidInCapital | 774.57M | 433.22M | 404.06M | 398.73M |
| CapitalStock | 1.00K | 1.00K | 7.00K | 7.00K |
| CommonStock | 1.00K | 1.00K | 7.00K | 7.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 51.49M | 75.24M | 61.92M | 53.75M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.93M | 7.82M | 20.52M | 19.73M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 4.25M | ||
| NonCurrentDeferredLiabilities | 4.25M | 20.52M | 18.41M | |
| NonCurrentDeferredRevenue | 4.25M | 20.52M | 18.41M | |
| LongTermDebtAndCapitalLeaseObligation | 1.93M | 3.58M | 0.00 | 1.32M |
| LongTermCapitalLeaseObligation | 1.93M | 3.58M | 0.00 | 1.32M |
| CurrentLiabilities | 49.55M | 67.42M | 41.40M | 34.02M |
| OtherCurrentLiabilities | 24.66M | |||
| CurrentDeferredLiabilities | 0.00 | 430.00K | 14.61M | 13.92M |
| CurrentDeferredRevenue | 0.00 | 430.00K | 14.61M | 13.92M |
| CurrentDebtAndCapitalLeaseObligation | 1.64M | 1.30M | 1.21M | 3.74M |
| CurrentCapitalLeaseObligation | 1.64M | 1.30M | 1.21M | 1.15M |
| CurrentDebt | 2.59M | |||
| OtherCurrentBorrowings | 2.59M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.91M | 5.03M | 4.92M | 4.86M |
| PayablesAndAccruedExpenses | 43.00M | 35.99M | 20.65M | 11.50M |
| CurrentAccruedExpenses | 13.35M | 14.18M | 7.67M | 10.20M |
| Payables | 29.65M | 21.81M | 12.98M | 1.30M |
| TotalTaxPayable | 26.05M | 18.04M | 11.53M | |
| AccountsPayable | 3.61M | 3.77M | 1.45M | 1.30M |
| TotalAssets | 214.80M | 67.03M | 47.49M | 75.33M |
| TotalNonCurrentAssets | 4.06M | 6.17M | 2.39M | 3.63M |
| OtherNonCurrentAssets | 96.00K | 1.05M | 1.07M | 1.08M |
| NetPPE | 3.96M | 5.13M | 1.32M | 2.54M |
| AccumulatedDepreciation | -3.34M | -3.19M | -3.16M | -3.22M |
| GrossPPE | 7.31M | 8.32M | 4.48M | 5.77M |
| Leases | 425.00K | 425.00K | 425.00K | 425.00K |
| OtherProperties | 6.38M | 7.39M | 3.51M | 4.66M |
| MachineryFurnitureEquipment | 505.00K | 505.00K | 540.00K | 686.00K |
| BuildingsAndImprovements | 2.29M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 210.74M | 60.85M | 45.09M | 71.70M |
| OtherCurrentAssets | 12.87M | 1.71M | 6.53M | |
| AssetsHeldForSaleCurrent | 0.00 | 9.29M | ||
| RestrictedCash | 6.35M | 0.00 | 0.00 | 2.59M |
| PrepaidAssets | 6.53M | 4.07M | ||
| Inventory | 6.10M | 0.00 | ||
| FinishedGoods | 0.00 | 0.00 | ||
| WorkInProcess | 3.41M | 0.00 | ||
| RawMaterials | 2.69M | 0.00 | ||
| Receivables | 1.69M | 14.07M | 5.83M | 5.36M |
| AccountsReceivable | 1.69M | 14.07M | 5.83M | 5.36M |
| CashCashEquivalentsAndShortTermInvestments | 189.82M | 35.78M | 32.73M | 59.68M |
| CashAndCashEquivalents | 189.82M | 35.78M | 32.73M | 59.68M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -176.66M | -22.94M | -28.59M | -25.27M |
| RepaymentOfDebt | -276.00K | 0.00 | -2.59M | -4.44M |
| IssuanceOfCapitalStock | 337.33M | 25.96M | 2.36M | 49.03M |
| CapitalExpenditure | -129.00K | -505.00K | -118.00K | -41.00K |
| InterestPaidSupplementalData | 0.00 | 40.00K | 228.00K | |
| IncomeTaxPaidSupplementalData | 95.00K | 797.00K | 0.00 | |
| EndCashPosition | 196.18M | 35.78M | 32.73M | 62.27M |
| BeginningCashPosition | 35.78M | 32.73M | 62.27M | 42.95M |
| ChangesInCash | 160.40M | 3.05M | -29.54M | 19.32M |
| FinancingCashFlow | 337.06M | 25.98M | -951.00K | 44.60M |
| CashFlowFromContinuingFinancingActivities | 337.06M | 25.98M | -951.00K | 44.60M |
| NetOtherFinancingCharges | -39.00K | -720.00K | ||
| ProceedsFromStockOptionExercised | 46.00K | 21.00K | 0.00 | 6.00K |
| NetCommonStockIssuance | 337.33M | 25.96M | 2.36M | 49.03M |
| CommonStockIssuance | 337.33M | 25.96M | 2.36M | 49.03M |
| NetIssuancePaymentsOfDebt | -276.00K | 0.00 | -2.59M | -4.44M |
| NetLongTermDebtIssuance | -276.00K | 0.00 | -2.59M | -4.44M |
| LongTermDebtPayments | -276.00K | 0.00 | -2.59M | -4.44M |
| InvestingCashFlow | -129.00K | -505.00K | -118.00K | -41.00K |
| CashFlowFromContinuingInvestingActivities | -129.00K | -505.00K | -118.00K | -41.00K |
| NetPPEPurchaseAndSale | -129.00K | -505.00K | -118.00K | -41.00K |
| PurchaseOfPPE | -129.00K | -505.00K | -118.00K | -41.00K |
| OperatingCashFlow | -176.53M | -22.43M | -28.47M | -25.23M |
| CashFlowFromContinuingOperatingActivities | -176.53M | -22.43M | -28.47M | -25.23M |
| ChangeInWorkingCapital | -13.93M | -3.92M | 454.00K | 14.44M |
| ChangeInOtherWorkingCapital | -29.38M | -5.56M | 2.85M | 8.41M |
| ChangeInOtherCurrentLiabilities | -1.08M | -973.00K | -1.05M | 1.53M |
| ChangeInPayablesAndAccruedExpense | 7.00M | 15.39M | 1.57M | -1.09M |
| ChangeInAccruedExpense | 8.01M | 6.51M | 3.94M | |
| ChangeInPayable | -1.00M | 8.89M | -2.37M | |
| ChangeInAccountPayable | -1.00M | 8.89M | -2.37M | |
| ChangeInPrepaidAssets | -10.85M | 3.73M | -2.44M | -229.00K |
| ChangeInInventory | 6.10M | -6.10M | 0.00 | |
| ChangeInReceivables | 14.28M | -10.41M | -477.00K | 5.82M |
| ChangesInAccountReceivables | 14.28M | -10.41M | -477.00K | 5.82M |
| OtherNonCashItems | 3.09M | 1.24M | 982.00K | 15.00K |
| StockBasedCompensation | 3.91M | 3.06M | 3.53M | 4.01M |
| DepreciationAmortizationDepletion | 233.00K | 118.00K | 143.00K | -1.23M |
| DepreciationAndAmortization | 233.00K | 118.00K | 143.00K | -1.23M |
| Depreciation | 233.00K | 118.00K | 143.00K | -1.23M |
| NetIncomeFromContinuingOperations | -169.83M | -22.93M | -33.58M | -42.47M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CDTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|